Valuation: Nuvectra Corporation

Market Cap 1.7M 1.49M 1.38M 1.29M 2.41M 160M 2.46M 16.5M 6.39M 79.03M 6.38M 6.24M 275M P/E 2017
-1.84x
P/E 2018 -5.02x
Enterprise Value -53.46M -46.96M -43.26M -40.45M -75.87M -5.04B -77.26M -519M -201M -2.49B -201M -196M -8.64B EV / Sales 2017
2.58x
EV / Sales 2018 4.76x
Free-Float
96.76%
Yield 2017 *
-
Yield 2018 -
Manager TitleAgeSince
Chief Executive Officer 78 31/01/2019
Compliance Officer 51 01/01/2015
Director TitleAgeSince
Director/Board Member 67 01/03/2016
Director/Board Member 78 01/03/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+16.67% - - 268K
+3.04%+5.46%-32.14%-13.71% 162B
+0.49%+1.49%-6.34%-7.96% 103B
+0.87%+5.56%-1.84%+52.90% 55.83B
-2.09%-6.13%+51.65%+53.01% 54.05B
+2.44%+5.14%-11.42%-40.99% 41.71B
+4.77%+5.09% - - 31.94B
-1.58%-5.27%-18.93%-45.84% 26.49B
+1.81%+5.67%+56.80%-5.57% 24.48B
+1.66%+3.94%-12.39%-0.10% 20.52B
Average +0.64%+3.19%+3.17%-1.03% 52.05B
Weighted average by Cap. +1.17%+2.27%-6.19%-0.59%

Financials

2017 2018
Net sales 31.84M 27.96M 25.77M 24.09M 45.18M 3B 46.01M 309M 120M 1.48B 120M 117M 5.15B 48.83M 42.89M 39.52M 36.95M 69.3M 4.61B 70.58M 474M 184M 2.27B 183M 179M 7.89B
Net income -44.6M -39.18M -36.1M -33.75M -63.3M -4.21B -64.46M -433M -168M -2.07B -167M -164M -7.21B -48.13M -42.28M -38.95M -36.42M -68.31M -4.54B -69.56M -467M -181M -2.24B -181M -177M -7.78B
Net Debt -1.49M -1.31M -1.21M -1.13M -2.11M -141M -2.15M -14.47M -5.6M -69.31M -5.6M -5.47M -241M -55.16M -48.45M -44.64M -41.74M -78.28M -5.2B -79.72M -536M -207M -2.57B -207M -203M -8.92B
Logo Nuvectra Corporation
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
Employees
-
  1. Stock Market
  2. Stocks
  3. NVTRQ Stock